查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493316

製藥中心/病患訪問支援服務市場規模、佔有率和趨勢分析報告：按服務類型、服務提供類型、區域和細分市場預測：2024-2030

Pharma HUB And Patient Access Support Service Market Size, Share & Trends Analysis Report By Service Type (Program Enrollment, Treatment Navigators), By Service Delivery Type, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

製藥中心/病患訪問支援服務市場的成長和趨勢：

Grand View Research, Inc.最新報告顯示，2024年至2030年，全球製藥中心和病患准入支援服務市場將以9.9%的複合年成長率成長，到2030年將達到57億美元。

這一成長是由患有罕見疾病和需要獲得特定藥物的罕見疾病患者數量顯著增加所推動的。此外，強調建立以患者為中心的生態系統並在整個治療過程中為患者提供良好支持，以及對旨在改善患者治療效果的客製化解決方案不斷成長的需求也推動了市場的發展。

罕見疾病的流行正在推動製藥中心和患者獲取支援服務市場的成長。背景因素包括對特殊治療的需求、對罕見疾病藥物開發的獎勵、由於稀有性而支持患者獲取的需要、全球合作體係以及罕見疾病治療市場的擴大。這些因素導致製藥業的投資、創新和合作增加，特別是在罕見疾病研發和病患支援服務相關領域。

歐盟有多達 3,600 萬人受到罕見疾病的影響，疾病種類超過 6000 種。有些罕見疾病只影響少數人，而有些則影響多達 245,000 人。這些疾病中約 80% 具有遺傳根源，其中 70% 是在兒童時期形成的。此外，超過 10,000 種罕見疾病影響著美國超過 3,000 萬人。此外，據估計，印度有 6% 至 8% 的人口受到罕見和超罕見疾病的影響。因此，罕見疾病的顯著流行預計將有助於市場成長。

透過創建以患者為中心的生態系統，製藥公司將患者的需求放在第一位，並在整個治療過程中提供支持他們的服務。這是由於影響患者治療的多種因素造成的，包括缺乏適當的培訓、不遵守藥物治療、擔心副作用和錯過預約。一旦患者接受了特定治療方法，他們就可以存取相關的患者服務資源並開始與您的組織合作。

先進的分析和人工智慧技術為患者服務團隊提供了可行的見解，以隨著治療的進展滿足每位患者的個人需求。這種量身定做的方法可確保患者在正確的時間獲得正確的支持，從而改善治療結果。例如，Managed Markets Insight &Technology, LLC、IQVIA 和 IntegriChain 等公司提供此類解決方案來克服患者訪問障礙。

此外，生命科學產業正在適應數位時代，重點關注基於價值的護理和優先考慮綜合服務的結果主導模型。這種轉變導致了整合解決方案中技術進步的採用，從而改善了患者的就診並改善了醫療保健結果。 TrialCard 的新企業 SaaS PatientLink 平台就是一個例子。 PatientLink 於 2022 年 4 月推出，簡化了病患存取和參與病患援助計畫的過程，同時提高了用藥依從性。這是一種提供全通路體驗的高度可配置服務，生命科學領導者可以透過多系統互通性滿足苛刻的醫療保健市場的需求。

製藥中心/病患訪問支援服務市場報告亮點

  • 按服務類型分類，2023年節目註冊產業佔最大市場佔有率。這種成長是由於對客製化解決方案的需求不斷成長以及對改善患者治療效果的需求不斷成長而推動的。
  • 依服務提供類型分類，2023年綜合服務細分市場佔據最大市場佔有率。其優勢在於，整合解決方案提供了一個統一的平台來管理各種功能，例如病患存取協助、報銷協助和藥局協調。
  • 2023年，北美在全球市場中佔據最大的收益佔有率。這一成長歸因於糖尿病和心血管疾病等與文明病的增加、基於臨床試驗的研究的增加、該地區市場參與者的強大存在，並且美國和其他國家有許多已開發國家。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章製藥中心/病患訪問支援服務市場的變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 製藥中心/病患訪問支援服務市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19 的影響

第4章 製藥中心/病患訪問支援服務市場：服務類型估計與趨勢分析

  • 2023年及2030年服務類型市場佔有率
  • 細分儀表板
  • 全球製藥中心/病患訪問支援服務市場：按服務類型分類的展望
  • 節目註冊
  • 治療導航器
  • 報銷服務/平價服務
  • 臨床教育家
  • 專業藥房和配藥的協調
  • 其他

第5章 製藥中心/病患訪問支援服務市場：服務提供類型的估計和趨勢分析

  • 2023年及2030年服務提供類型的市場佔有率
  • 細分儀表板
  • 全球製藥中心和病患訪問支援服務市場：按服務交付類型分類的展望
  • 綜合服務
  • 獨立服務

第6章 製藥中心和病人訪問支援服務市場：區域估計和趨勢分析，按服務類型，按服務提供類型

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第7章 競爭格局

  • 最新趨勢與影響分析：主要市場參與企業
  • 公司/競爭對手分類
    • 創新者
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023年主要企業市場佔有率分析
    • PharmaCord
    • Fortrea
    • AssistRx
    • CareMetx
    • ConnectiveRx
    • Lash Group
    • McKesson
    • Inizio Engage
    • NS Pharma, Inc. (a wholly owned subsidiary of Nippon Shinyaku Co., Ltd.)
    • Sonexus Health (acquired by Cardinal Health)
    • Envoy Health Management, LLC (independently operated subsidiary of Diplomat Pharmacy, Inc.)
    • EVERSANA
    • United BioSource LLC (UBC)
    • Mercalis
Product Code: GVR-4-68040-278-6

Pharma HUB And Patient Access Support Service Market Growth & Trends:

The global pharma HUB and patient access support service market size is expected to reach USD 5.7 billion by 2030, registering a CAGR of 9.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the significant prevalence of rare and orphan-diseased patients requiring access to specific medicines. Furthermore, the market is driven by an emphasis on establishing a patient-centered ecosystem to provide extensive support to patients throughout their treatment and an increasing demand for tailored solutions aimed at improving patient outcomes.

The prevalence of rare diseases has fueled growth in the pharmaceutical hub and patient access support service market. It is driven by specialized treatment demand, incentives for orphan drug development, the need for patient access support due to rarity, global collaborative efforts, and an expanding market for rare disease treatments. These factors have led to increased investment, innovation, and collaboration in the pharmaceutical industry, particularly in areas related to rare disease research, development, and patient support services.

Up to 36 million people in the EU are affected by rare diseases, which encompass over 6,000 distinct conditions. While some rare diseases impact only a few patients, others can affect as many as 245,000 individuals. About 80% of these diseases have genetic roots, with 70% beginning in childhood. Furthermore, in the U.S., over 10,000 rare diseases impact more than 30 million people. Moreover, it's estimated that 6-8% of the population in India is affected by rare or ultra-rare diseases. Hence, the significant prevalence of rare diseases is expected to contribute to the market growth.

Pharmaceutical companies are prioritizing the needs of patients by creating a patient-centric ecosystem that offers services to support them throughout their therapy journey. This is due to various factors such as lack of proper training, medication non-adherence, and fear of adverse effects, or missed appointments, which can affect a patient's treatment. Patients can access relevant patient service resources and start engaging with the organization as soon as they are prescribed a particular therapy.

With advanced analytics and AI technology, patient services teams can now obtain actionable insights to cater to each patient's individual needs as they progress through their treatment journey. This tailored approach ensures that patients receive the right support at the right time, leading to better therapy outcomes. For instance, companies such as Managed Markets Insight & Technology, LLC, IQVIA, & IntegriChain are offering such solutions in order to overcome barriers to patient access.

Furthermore, the life sciences industry is adapting to the digital era by focusing on value-based care and outcome-driven models that prioritize integrated services. This shift has led to the adoption of technological advancements in integrated solutions to enhance patient access and improve healthcare outcomes. One such example is the PatientLink platform, a new enterprise SaaS by TrialCard. Launched in April 2022, PatientLink simplifies patient access and engagement with Patient Support Programs while improving adherence to medication. It is a highly configurable service that offers an omnichannel experience, enabling leaders in life sciences to meet the needs of a demanding healthcare marketplace through multi-system interoperability.

Pharma HUB And Patient Access Support Service Market Report Highlights:

  • Based on service type, the program enrollment segment held the largest market share in 2023. Its growth can be attributed to growing demand for customized solutions and the increasing need to improve patient outcomes drive
  • Based on service delivery type, the integrated services segment held the largest market share in 2023. Its dominance is because the integrated solutions offer a unified platform to manage various functions such as patient access support, reimbursement assistance, and pharmacy coordination
  • North America dominated the global market with the largest revenue share in 2023. Its growth can be attributed to the rising prevalence of lifestyle-associated diseases, such as diabetes & cardiovascular disorders, growing number of clinical trial-based research, strong presence of market players in the region, and presence of developed countries, such as the U.S.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Service Type
    • 1.1.2. Service Delivery Type
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
    • 1.6.3. Volume price analysis (Model 2)
    • 1.6.4. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Service type outlook
    • 2.2.2. Service delivery type outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Pharma HUB And Patient Access Support Service Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Pharma HUB And Patient Access Support Service Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & legal landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social & environmental landscape
      • 3.3.2.4. Technological landscape
    • 3.3.3. Impact of COVID-19

Chapter 4. Pharma HUB And Patient Access Support Service Market: Service Type Estimates & Trend Analysis

  • 4.1. Service Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Pharma HUB And Patient Access Support Service Market by Service Type Outlook
  • 4.4. Program Enrollment
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.4.2. Order processing
      • 4.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.4.3. Application processing
      • 4.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.4.4. Ease of enrollment (through phone, face, portal, or app)
      • 4.4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.4.5. Program data
      • 4.4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. Treatment Navigators
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.2. Process flows and standard operating procedures
      • 4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.3. Program literature and scripts
      • 4.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.4. Care team training
      • 4.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.5. Systems testing and optimization
      • 4.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.6. Reimbursement Services/Affordability Services
    • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.7. Clinical Educator
    • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.8. Coordination of Specialty Pharmacy/Dispensing
    • 4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Pharma HUB And Patient Access Support Service Market: Service Delivery Type Estimates & Trend Analysis

  • 5.1. Service Delivery Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Pharma HUB And Patient Access Support Service Market by Service Delivery Type Outlook
  • 5.4. Integrated Services
    • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5. Standalone Services
    • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Pharma HUB And Patient Access Support Service Market: Regional Estimates & Trend Analysis, By Service Type, By Service Delivery Type

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Denmark
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Norway
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Mexico
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
    • 7.2.1. Innovators
    • 7.2.2. List of key distributors and channel partners
    • 7.2.3. Key customers
    • 7.2.4. Key company market share analysis, 2023
    • 7.2.5. PharmaCord
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Fortrea
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. AssistRx
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. CareMetx
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. ConnectiveRx
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Lash Group
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. McKesson
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. Inizio Engage
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives
    • 7.2.13. NS Pharma, Inc. (a wholly owned subsidiary of Nippon Shinyaku Co., Ltd.)
      • 7.2.13.1. Company overview
      • 7.2.13.2. Financial performance
      • 7.2.13.3. Product benchmarking
      • 7.2.13.4. Strategic initiatives
    • 7.2.14. Sonexus Health (acquired by Cardinal Health)
      • 7.2.14.1. Company overview
      • 7.2.14.2. Financial performance
      • 7.2.14.3. Product benchmarking
      • 7.2.14.4. Strategic initiatives
    • 7.2.15. Envoy Health Management, LLC (independently operated subsidiary of Diplomat Pharmacy, Inc.)
      • 7.2.15.1. Company overview
      • 7.2.15.2. Financial performance
      • 7.2.15.3. Product benchmarking
      • 7.2.15.4. Strategic initiatives
    • 7.2.16. EVERSANA
      • 7.2.16.1. Company overview
      • 7.2.16.2. Financial performance
      • 7.2.16.3. Product benchmarking
      • 7.2.16.4. Strategic initiatives
    • 7.2.17. United BioSource LLC (UBC)
      • 7.2.17.1. Company overview
      • 7.2.17.2. Financial performance
      • 7.2.17.3. Product benchmarking
      • 7.2.17.4. Strategic initiatives
    • 7.2.18. Mercalis
      • 7.2.18.1. Company overview
      • 7.2.18.2. Financial performance
      • 7.2.18.3. Product benchmarking
      • 7.2.18.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America pharma HUB and patient access support service market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 4 North America pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 5 U.S. pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 6 U.S. pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 7 Canada pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 8 Canada pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 9 Europe pharma HUB and patient access support service market, by region, 2018 - 2030 (USD Million)
  • Table 10 Europe pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 11 Europe pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 12 Germany pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 13 Germany pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 14 UK pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 15 UK pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 16 France pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 17 France pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 18 Italy pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 19 Italy pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 20 Spain pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 21 Spain pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 22 Denmark pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 23 Denmark pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 24 Sweden pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 25 Sweden pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 26 Norway pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 27 Norway pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific pharma HUB and patient access support service market, by region, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 31 China pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 32 China pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 33 Japan pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 34 Japan pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 35 India pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 36 South Korea pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 37 South Korea pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 38 Australia pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 39 Australia pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 40 Thailand pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 41 Thailand pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 42 Latin America pharma HUB and patient access support service market, by region, 2018 - 2030 (USD Million)
  • Table 43 Latin America pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 44 Latin America pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 45 Brazil pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 46 Brazil pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 47 Mexico pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 48 Mexico pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 49 Argentina pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 50 Argentina pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 51 MEA pharma HUB and patient access support service market, by region, 2018 - 2030 (USD Million)
  • Table 52 MEA pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 53 MEA pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 54 South Africa pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 55 South Africa pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 58 UAE pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 59 UAE pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)
  • Table 60 Kuwait pharma HUB and patient access support service market, by service type, 2018 - 2030 (USD Million)
  • Table 61 Kuwait pharma HUB and patient access support service market, by service delivery type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Pharma HUB and patient access support service market: market outlook
  • Fig. 9 Credentialing software and services competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Pharma HUB and patient access support service market driver impact
  • Fig. 15 Pharma HUB and patient access support service market restraint impact
  • Fig. 16 Pharma HUB and patient access support service market strategic initiatives analysis
  • Fig. 17 Pharma HUB and patient access support service market: Service type movement analysis
  • Fig. 18 Pharma HUB and patient access support service market: Service type outlook and key takeaways
  • Fig. 19 Program enrollment market estimates and forecast, 2018 - 2030
  • Fig. 20 Order processing market estimates and forecast, 2018 - 2030
  • Fig. 21 Application processing market estimates and forecast, 2018 - 2030
  • Fig. 22 Ease of enrollment (through phone, face, portal, or app) market estimates and forecast, 2018 - 2030
  • Fig. 23 Program data market estimates and forecast, 2018 - 2030
  • Fig. 24 Treatment navigators market estimates and forecast, 2018 - 2030
  • Fig. 25 Process flows and standard operating procedures market estimates and forecast, 2018 - 2030
  • Fig. 26 Program literature and scripts market estimates and forecast, 2018 - 2030
  • Fig. 27 Care team training market estimates and forecast, 2018 - 2030
  • Fig. 28 Systems testing and optimization market estimates and forecast, 2018 - 2030
  • Fig. 29 Reimbursement services/affordability services market estimates and forecast, 2018 - 2030
  • Fig. 30 Clinical educator market estimates and forecast, 2018 - 2030
  • Fig. 31 Coordination of specialty pharmacy/dispensing market estimates and forecast, 2018 - 2030
  • Fig. 32 Others market estimates and forecast, 2018 - 2030
  • Fig. 33 Pharma HUB and patient access support service market: Service delivery type movement analysis
  • Fig. 34 Pharma HUB and patient access support service market: Service delivery type outlook and key takeaways
  • Fig. 35 Integrated services market estimates and forecast, 2018 - 2030
  • Fig. 36 Standalone services market estimates and forecast, 2018 - 2030
  • Fig. 37 Pharma HUB and patient access support service market: Regional movement analysis
  • Fig. 38 Pharma HUB and patient access support service market: Regional outlook and key takeaways
  • Fig. 39 Pharma HUB and patient access support service market share and leading players
  • Fig. 40 North America market share and leading players
  • Fig. 41 Europe market share and leading players
  • Fig. 42 Asia Pacific market share and leading players
  • Fig. 43 Latin America market share and leading players
  • Fig. 44 Middle East & Africa market share and leading players
  • Fig. 45 North America: SWOT
  • Fig. 46 Europe SWOT
  • Fig. 47 Asia Pacific SWOT
  • Fig. 48 Latin America SWOT
  • Fig. 49 MEA SWOT
  • Fig. 50 North America, by country
  • Fig. 51 North America
  • Fig. 52 North America market estimates and forecasts, 2018 - 2030
  • Fig. 53 U.S.
  • Fig. 54 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 55 Canada
  • Fig. 56 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 57 Europe
  • Fig. 58 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 59 UK
  • Fig. 60 UK market estimates and forecasts, 2018 - 2030
  • Fig. 61 Germany
  • Fig. 62 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 63 France
  • Fig. 64 France market estimates and forecasts, 2018 - 2030
  • Fig. 65 Italy
  • Fig. 66 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 67 Spain
  • Fig. 68 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 69 Denmark
  • Fig. 70 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 71 Sweden
  • Fig. 72 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 73 Norway
  • Fig. 74 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 75 Asia Pacific
  • Fig. 76 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 77 China
  • Fig. 78 China market estimates and forecasts, 2018 - 2030
  • Fig. 79 Japan
  • Fig. 80 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 81 India
  • Fig. 82 India market estimates and forecasts, 2018 - 2030
  • Fig. 83 Thailand
  • Fig. 84 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 85 South Korea
  • Fig. 86 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 87 Australia
  • Fig. 88 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 89 Latin America
  • Fig. 90 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 91 Brazil
  • Fig. 92 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 93 Mexico
  • Fig. 94 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 95 Argentina
  • Fig. 96 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 97 Middle East and Africa
  • Fig. 98 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 99 South Africa
  • Fig. 100 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 101 Saudi Arabia
  • Fig. 102 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 103 UAE
  • Fig. 104 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 105 Kuwait
  • Fig. 106 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 107 Market share of key market players- Pharma HUB and patient access support service market